Items 11 to 14 of 14 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
CGP 57380 | 522629-08-9 | sc-202993 | 5 mg | $172.00 | 6 | |
CGP 57380 acts by binding to the ATP-binding site within the kinase domain of Lck. This binding interferes with the kinase's ability to transfer phosphate groups from ATP to target proteins, which is a critical step in its enzymatic activity. | ||||||
Lck Inhibitor III | 1188890-30-3 | sc-311372 | 5 mg | $660.00 | ||
Lck Inhibitor III functions as a selective inhibitor of the Lck enzyme, exhibiting unique binding dynamics through hydrophobic interactions and van der Waals forces with critical residues in the active site. This compound stabilizes an inactive conformation of Lck, preventing substrate access. Its kinetic profile reveals a rapid initial binding phase followed by a slower dissociation, ensuring prolonged inhibition. Additionally, the compound's structural characteristics facilitate enhanced specificity for Lck, minimizing off-target effects. | ||||||
Anomalin A | 548740-86-9 | sc-364099 | 1 mg | $133.00 | ||
Anomalin A acts as a potent Lck inhibitor, characterized by its ability to disrupt the enzyme's phosphorylation activity. It engages in specific hydrogen bonding and electrostatic interactions with key amino acid residues, effectively altering the enzyme's conformation. The compound exhibits a unique allosteric modulation, influencing the enzyme's catalytic efficiency. Its reaction kinetics demonstrate a biphasic binding pattern, allowing for sustained inhibition while maintaining selectivity against similar kinases. | ||||||
A 419259 trihydrochloride | 1435934-25-0 | sc-361094 | 5 mg | $213.00 | 6 | |
A 419259 trihydrochloride acts as a potent Lck inhibitor, characterized by its ability to disrupt the enzyme's active site through specific electrostatic interactions. This compound exhibits a unique binding affinity, stabilizing an inactive conformation of Lck. Its kinetic profile reveals a fast initial binding phase, followed by a gradual transition to a stable complex, effectively altering downstream signaling cascades. The compound's solubility properties further enhance its interaction dynamics within cellular environments. | ||||||